DNAs(Genentech) Avastin was approved about a year ago for use on colon cancer . The $11B jump was just for the new approval for Avastin on NSCLC . Indications are that Coramsine will raise the bar considerably higher again . It is my guess that Solbec will probably concentrate on orphan drug uses , such as melonoma and mesothelioma with the prospect of accellerated approval before trials are completed .
SBP
solbec pharmaceuticals limited
genentech up $11 billion, page-4
Add to My Watchlist
What is My Watchlist?